Neratinib and afatinib are irreversible molecular inhibitors of HER2, EGFR and HER 4 approved by the FDA to treat EGFR-positive non-small and squamous lung cancer and HER2 positive breast cancer, which both demonstrate a significant activity against primary HER@-amplified cell lines and xenografts. Here, ERBB2 is linked to breast cancer.